BACKGROUND: After severe trauma, patients develop a norepinephrine-mediated persistent, injury-associated anemia. This anemia is associated with suppression of bone marrow (BM) erythroid colony growth, along with decreased iron levels, and elevated erythropoietin (EPO) levels, which are insufficient to promote effective erythropoiesis. The impact of norepinephrine on iron regulators, such as ferroportin, transferrin, and transferrin receptor-1 (TFR-1), is unknown. Using a clinically relevant rodent model of lung contusion (LC), hemorrhagic shock (HS), and chronic stress (CS), we hypothesize that daily propranolol (BB), a nonselective β blocker, restores BM function and improves iron homeostasis.
I
mmediately after trauma, severely injured patients experience a hypercatecholamine state as well as an inflammatory response to injury. 1, 2 This initial sympathetic response is physiologic but when the hypercatecholamine state persists in critical illness it is damaging to vital organs. [2] [3] [4] Both the bone marrow (BM) and the liver are highly innervated by the sympathetic nervous system. 5, 6 Previous work with in vitro and vivo models demonstrated that norepinephrine (NE) rather than epinephrine was a key modulator of hematopoietic progenitor cell mobilization and an inhibitor of BM erythroid cell growth. [7] [8] [9] In the liver, NE can directly stimulate interleukin-6 (IL-6), a key proinflammatory cytokine. 6 ,10 IL-6 increases liver hepcidin, the main regulator of iron homeostasis that alters iron availability. 10, 11 The true incidence of iron deficiency or functional iron deficiency in trauma patients is unknown. 12 While the etiology of anemia after trauma is multifactorial, the assessment of iron restriction is challenging to define in the context of persistent inflammation. 12 Yet, after severe trauma in humans and in rodent models of injury/ shock/stress, the persistent elevation of NE is associated with BM dysfunction and a persistent injury-associated anemia. [13] [14] [15] In addition, in the context of tissue injury and hemorrhagic shock (HS)-induced BM dysfunction, propranolol has been shown to reduce hematopoietic progenitor cell mobilization and reduce suppression of BM erythroid colony growth. [15] [16] [17] The effect of severe trauma and chronic stress (CS) on iron metabolism has not been clearly defined. The liver plays an essential role, as the primary site for production of ironregulating proteins and as a storage site for excess iron, which may be mobilized to the circulation to meet metabolic requirements. 18 Ferroportin, the sole exporter of iron, releases iron from hepatocytes into the circulation and hepcidin regulates iron by degrading ferroportin to block iron release. 18, 19 Transferrin, a plasma glycoprotein, has a high affinity for iron and transports it to other tissues. 11, 20 After blood loss, the maturation of erythroid cells are necessary for production of red blood cells and developing erythrocytes have high iron demand. 21, 22 The uptake of iron in erythroid cells is mediated by transferrin and its receptor, transferrin receptor-1 (TFR-1). 23 Approximately 80% of TFR-1 is located in BM erythroid cells. 23 Erythropoietin (EPO) is essential in the early stages of erythroid cell growth, including the survival of colony-forming unit erythroid cells (CFUEs). 24 Hepcidin also plays an important role in effective erythropoiesis. Under normal homeostasis, there is a balance of the EPO-hepcidin axis. After severe injury, plasma EPO levels are high relative to the degree of anemia. 25 Previous work in severe trauma and CS has demonstrated that EPO suppresses plasma hepcidin and iron levels remain low and anemia persists. 26, 27 In this study, we use a rodent model of lung contusion (LC), HS, and CS to evaluate iron regulation and BM erythroid function. We hypothesize that daily administration of propranolol (BB) after LCHS/CS restores BM erythroid function, improves iron homeostasis, and abrogates persistent injuryassociated anemia.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (Charles River, Wilmington, MA), weighing 280 to 315 g were housed in pairs with free access to food and water during daily night/day cycles of 12 hours each. Female animals were excluded due to estrous cycle variability and its impact after HS. The animal protocol had been approved by the University of Florida Institutional Animal Care and Use Committee.
Experimental Design
Rodents were randomly assigned into one of the five groups (n = 8/group): 1) naïve control; 2) LC followed by hemorrhagic shock (LCHS); 3) LCHS + propranolol hydrochloride (LCHS + BB) (Sigma-Aldrich, St Louis, MO); 4) LCHS followed by daily CS (LCHS/CS); 5) LCHS/CS + BB. Propranolol (10 mg/kg) was administered by the intraperitoneal route ten minutes after LCHS and daily for six days. In groups subject to LCHS/CS, BB was given daily immediately after CS. Naïve rodents underwent daily handling. All groups were sacrificed on day 7. Liver, BM, and peripheral blood samples were collected and stored in a −80°C freezer.
LC and HS
As previously described, after intraperitoneal pentobarbital, a unilateral LC was made by a percussive nail gun (Sears Brand, Chicago, IL) applied directly to a 12-mm metal plate that was placed in the right axilla of the rodent. 15 Ten minutes after LC, the right femoral artery and right internal jugular vein were cannulated using heparinized saline (10 units/mL). The femoral artery tubing was connected to a continuous BP-2 Digital Blood Pressure Monitor device (Columbus Instruments, Columbus, OH) for measurement of mean arterial pressure and heart rate. Blood was then withdrawn from the internal jugular to maintain a mean arterial pressure of 30 to 35 mm Hg for 45 minutes. Shed blood is then reinfused.
Chronic Restraint Stress
CS consisted of 2 hours of restraint in a nose cone rodent cylinder (Kent Scientific Corporation, Torrington, CT, USA) daily for 6 days.
14 Rodents were repositioned in the cylinder every 30 minutes to prevent habituation and during which alarms sounded for two minutes. Those rodents in LCHS models were restricted from food and water during CS periods.
Hemoglobin Analysis
Heparinized blood samples were used for the analysis of hemoglobin using a VetScan HM5 Hematology Analyzer (Abaxis, CA).
BM Cellularity and Erythroid Progenitor Colonies
BM was harvested from the left femur using a 19-gauge needle and flushing 1 mL of Iscove Modified Dulbecco Medium (Lonza, Walkersville, MD) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA). BM cell viability was determined by 0.4% Trypan blue staining and cellularity was assessed on a hemocytometer.
As previously described, BM erythroid progenitor colony growth assays, including CFU granulocyte, erythrocyte, monocyte megakaryocyte (CFU-GEMM), burst-forming unit erythroid (BFU-E), and CFU-E were performed. 16, 17 Briefly, BM mononuclear cells at 1 Â 10 6 cells/mL in Iscove Modified Dulbecco Medium were plated in duplicate with Methocult media (Stemcell, Vancouver, BC, Canada). Plates were supplemented with 1.3 U/mL rhEPO and 6 U/mL rhIL-3 for BFU-E and CFU-E or 3 U/mL rhGM-CSF for CFU-GEMM. Plates were then incubated at 37°C in 5% CO 2 incubator. A blinded reader assessed colony growth of CFU-E on day 7 BFU-E colonies on day 14, and CFU-GEMM on day 17.
EPO and Hepcidin Measurements
Plasma EPO was evaluated using the standard sandwich Enzyme linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) and plasma hepcidin was measured using the standard competitive ELISA kit (MyBioSource.com, San Diego, CA). All samples were run in duplicate following the manufacturer's protocol.
Ferroportin, Transferrin, and TFR-1 Expression
Liver and BM RNA were isolated used RNeasy Mini Kit (Qiagen, Germantown, MD). Complementary DNA (cDNA) was then prepared from the RNA using a cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). Liver ferroportin (35 cycles; annealing temperature, 56°C), BM transferrin (35 cycles; annealing temperature, 54°C) and TFR-1 (32 cycles; annealing temperature, 56°C) polymerase chain reaction was performed using the following primers: ferroportin: 5-CCCTGCTCTGGCTGTAAAAG-3, 5-TAGGAGA CCCATCCATCTCG-3, transferrin: 5-TCAAGAGCTGCTGCAG AAAA-3,5-CCTGTTCCCACACTGGACTT-3, TFR-1: 5-TCTGA CCCTCACTGGGATTC-3, 5-GCCAAAAACGACAGAGCTTC-3. The following β-actin primers (annealing temperature 60°C) were used: 5-AGCCATGTACGTAGCCATCC-3, 5-CTCTCAG CTGTGGTGGTGAA-3. Amplified bands were visualized with 1.5% agarose gels and densitometry was measured using Image Processing and Analysis (ImageJ-NIH, Bethesda, MD).
Statistical Analysis
Graph Pad Prism Version 6 (San Diego, CA) was used to perform all statistical analysis. All data were presented as mean ± standard deviation and assessed for normality using the D'Agostino/Pearson omnibus test. Normally distributed variables were compared using t tests while Mann-Whitney U test was used to compare all other variables. Significance was defined as *p < 0.05 versus naïve controls and **p < 0.05 versus untreated counterpart. Figure 1A demonstrates that seven days of LCHS and LCHS/CS resulted in a significant decrease in BM cellularity by 24-27% compared to naïve. However, daily BB administration to LCHS and LCHS/CS rodents significantly improved cellularity compared to untreated counterparts (Fig. 1A) . The use of BB after LCHS and LCHS/CS restored BM cellularity to that of naïve animals.
RESULTS
Propranolol Restored Erythroid Function
On day 7, LCHS and LCHS/CS resulted in suppression of BM CFU-GEMM, BFU-E, and CFU-E erythroid progenitor colonies (Fig. 1B-D) . The addition of CS to LCHS resulted in an additional 10% to 20% suppression of CFU-GEMM, BFU-E, and CFU-E colonies compared to LCHS alone (Fig. 1B-D) . Daily BB administration after LCHS and LCHS/CS significantly improved BM CFU-GEMM, BFU-E, and CFU-E colony growth by 9% to 39% as compared with untreated counterparts (Fig. 1B-D) . Daily BB administration after LCHS and LCHS/ CS also improved BM erythroid function.
Propranolol Improves Anemia
Seven days after LCHS alone, there was a mild anemia but the addition of CS to LCHS resulted in a moderate persistent anemia compared with naïve (LCHS: 12.9 ± 1.0; LCHS/CS: 10.8 ± 0.8; naïve: 14.3 ± 0.4 g/dL). Daily BB administration after LCHS alone significantly improved hemoglobin levels (Fig. 2) . After LCHS/CS, the model that produced the most significant persistent anemia, the use of daily BB administration improved hemoglobin levels by 20% versus untreated counterparts (LCHS/CS ± BB: 13.7 ± 0.4 vs. LCHS/CS: 10.8 ± 0.8 g/dL) (Fig. 2) .
The Impact of Propranolol on Ferroportin, Transferrin, TFR-1
Ferroportin is the sole exporter of iron to all cells, especially erythroblasts, which need iron for maturation. 10, 18 Compared to naive, liver ferroportin expression after LCHS and LCHS/CS was significantly reduced by 38% and 69%, respectively (Fig. 3A) . The use of daily BB after LCHS increased liver ferroportin expression by nearly 50% (Fig. 3A) . The daily use of BB after LCHS/CS significantly increased ferroportin expression by 75% (Fig. 3A) .
Iron uptake in erythroblasts is facilitated by transferrin and its receptor, TFR-1. 23 Seven days after LCHS and LCHS/CS, BM transferrin production was significantly decreased by 48% and 88% respectively compared to compared to naive (Fig. 3B) . The daily use of BB after LCHS and LCHS/CS significantly increased BM transferrin expression compared to untreated counterparts (Fig. 3B) .
Seven days after LCHS, TFR-1 expression was similar to that of naïve animals (Fig. 3C) . After LCHS/CS, TFR-1 expression decreased 41% compared to naïve (Fig. 3C) . BM TFR-1 expression increased 21% with use of BB after LHCS and 45% with use of BB after LCHS/CS (Fig. 3C) . Propranolol administration after LCHS and LCHS/CS restored iron uptake and delivery to erythrocytes.
The Effect on Propranolol on the EPO-Hepcidin Axis
Seven days after LCHS and LCHS/CS animals exhibited mild-moderate anemia, and there was persistent elevation of plasma EPO (Fig. 4A) . Seven days after LCHS + BB, plasma EPO levels were decreased compared with LCHS (LCHS ± BB: 26.2 ± 8.3** vs. LCHS: 42.4 ± 5.3 pg/mL). Daily use of BB after LCHS/CS resulted in a 61% reduction in plasma EPO levels compared with LCHS/CS (Fig. 4A) .
Systemic iron homeostasis is mediated by hepcidin. 28 Figure 4B illustrates that plasma hepcidin levels were significantly decreased after LCHS and LCHS/CS. With daily administration of BB, plasma hepcidin increased 85% after LCHS and 86% after LCHS/CS (Fig. 4B ). Daily use of BB after LCHS and LCHS/CS restored the EPO-hepcidin axis.
DISCUSSION
After severe trauma in humans and in a rodent model of injury/shock/stress, the persistent elevation of NE is associated with BM dysfunction that manifests clinically as a persistent injury-associated anemia. 13, 14 Previous work demonstrated that daily propranolol administration after LCHS/CS decreased the prolonged mobilization of hematopoietic progenitor cells from the BM and decreased plasma G-CSF levels. 15 However, the impact of propranolol after LCHS/CS on BM erythroid cell function and iron homeostasis has not been previously described. This study supports previous work demonstrating the benefits of propranolol on BM erythroid function, by employing a unique rodent model of LC/HS followed by CS. The use of propranolol after LCHS/CS improved BM cellularity, BM erythroid colony growth, and hemoglobin levels. In addition, daily propranolol use after LCHS and LCHS/CS increased expression of liver ferroportin and BM transferrin, and BM TFR-1 expression. In the LCHS/CS group, once the anemia has resolved with the use of propranolol, the EPO-hepcidin axis is also restored.
Previously, the addition of daily CS to LCHS has resulted in BM dysfunction due to prolonged hematopoietic progenitor cell mobilization from the BM, decreased BM cellularity, and decreased erythroid colony growth. 13, 14 In this study, we demonstrate the benefit of daily propranolol use after LCHS and LCHS. This is most apparent in the LCHS/CS model, in which moderate anemia is resolved with use of propranolol. These results parallel the persistent anemia seen in critically ill trauma patients, which is also improved with the use of propranolol early after resuscitation. 12 The physiologic response severe trauma includes sympathetic activation followed by a catecholamine surge. 1, 3 However, when the sympathetic response is prolonged this leads to end organ dysfunction, most commonly studied in the cardiac system. 2 Previous work has revealed that NE and G-CSF mediate the mobilization of hematopoietic progenitor cells from the BM to sites of injury, decreasing the number of erythroid progenitor cells available for maturation. 5, 15 In addition, the use of daily clonidine after LCHS/CS prevented prolonged hematopoietic progenitor cell mobilization, improved BM function, and restored hemoglobin levels. 29 Clonidine is a central sympatholytic that inhibits the release of NE. Based on the current study and previous work by Alamo et al., 29 NE is likely the key mediator of BM dysfunction after trauma.
The liver is well innervated by the sympathetic nervous system and is a central component of iron production. This study sought to determine if prolonged elevation of NE had negative effects on iron metabolism. Seven days after LCHS and LCHS/CS, liver ferroportin expression was decreased and this finding correlated with decreased iron levels after trauma. 12 Similarly, Naz et al. 11 demonstrated a 30-50% decrease in liver ferroportin expression at 24 hours in a rodent model of tissue injury. Also, in vitro hepatocytes treated with interleukin-6 reduced liver ferroportin by 90% at 24 hours.
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In this study, daily propranolol use after LCHS and LCHS/CS significantly improved liver ferroportin expression. Ferroportin expression is impacted by inflammatory states, such as severe trauma and CS as well as HS. The proposed relationship between a NE-mediated hypercatecholamine state, the release of pro-inflammatory cytokines, and iron metabolism is illustrated in Figure 5A .
In addition to the presence of ferroportin, BM transferrin and TFR-1 are necessary for iron delivery into developing erythroid cells. 23 Previous work by Fitzsimons et al. 30 demonstrated that patients with anemia of chronic disease have low serum iron levels, and erythroblast TFR-1 expression is reduced by 39%. Seven days after LCHS/CS, both BM transferrin and TFR-1 expression are reduced. Sandrini et al. 20 showed that human serum transferrin incubated with NE caused decreased iron-transferrin signaling. In Figure 5B , we hypothesize that NE disrupts the iron-transferrin complex by decreasing iron availability, decreasing transferrin, or both. The use of propranolol after LCHS and LCHS/CS increased transferrin and TFR-1 expression by competitively blocking NE from binding to its β receptors.
Immediately after blood loss, effective erythropoiesis requires that EPO is upregulated, whereas hepcidin is reduced. 31, 32 Critically injured patients often have moderate to severe persistent anemia despite elevation of EPO.
25,33 Naz et al. 11 demonstrated that that severe tissue injury in rodents suppressed ferroportin before hepcidin levels were detectable. In our study, liver ferroportin expression was reduced despite low plasma hepcidin levels. This may explain why plasma iron levels are low after trauma and why these patients remain anemic despite the use of exogenous iron. 34 The use of propranolol after LCHS/CS improved hemoglobin levels and this correlated with a decrease in plasma EPO levels while plasma hepcidin levels improved. The effects of daily propranolol treatment on plasma EPO levels were most likely secondary to improved hemoglobin levels. This finding demonstrates an inverse relationship between EPO and hepcidin after severe trauma and CS. The etiology of persistent injury-associated anemia is multifactorial but there is strong evidence that CS and NE play a significant role.
Currently, blood transfusions remain the mainstay of treatment for anemia and despite transfusion restrictive practices, trauma patients are more likely to be transfused than nontrauma patients. 35 Outcomes for those receiving transfusions has been linked to increased hospital stay, infection, and lung injury. 36 Both the use of intravenous iron and erythropoiesis stimulating agents in critically ill trauma patients have failed to show morbidity benefit or transfusion reduction. 34, 37, 38 The search for alternative therapies for anemia treatment remains a priority, as professional societies and other organizations work to develop hospital wide blood management programs to improve outcomes and reduce costs. This study demonstrates that after severe trauma and CS decreased BM erythroid progenitor cell growth is due in part to decreased iron availability. It is likely the reduction of NE rather than the blockage of a specific β receptor that causes a disruption in the iron transport system. Daily use of propranolol after severe trauma and CS restored BM function, improved iron homeostasis, and restored the EPO-hepcidin axis. Thus, future investigations targeting the prolonged stress response after trauma may be prove to be beneficial in treating critically injured patients with persistent anemia. In a rat model of hemorrhagic shock and chronic stress, the authors demonstrated that propranolol treatment improved hemoglobin concentration, bone marrow cellularity, and iron transport system. This is an important translational study that points to a future potential therapy in the critically-ill patients. I have three questions and a comment.
You used propranolol, a non-selective beta-blocker. Previous studies from your lab have demonstrated the importance of specific beta receptors in the bone marrow erythroid cell growth and mobilization. Do you know which receptors are important in iron transport system and regulation of Hepcidin expression?
You demonstrated that beta-blockers attenuated Hepcidin expression, thereby improved iron release via Ferroportin. Was this effect mediated via IL-6 expression? Did you measure systemic IL-6 expression?
The lower EPO levels seen with beta-blocker therapy, was it due to direct beta-blocker effect or do you think secondary to improved hemoglobin concentration?
And my final comment. There have been many studies looking at beta-blocker treatment in the critically-ill. We and others have shown that beta-blockers improve the outcome in the injured patients, especially patients with head injury.
Others have shown decreased infectious complications and improved nutritional status. Your lab has shown improved erythroid bone marrow population and iron transportation.
It is time for all of us to get together and do a large, multiinstitutional, randomized study investigating the potential benefits of beta-blockers in the trauma patients.
Again, I want to congratulate the authors on an outstanding study. I also want to thank the AAST for the opportunity to discuss this paper. Thank you.
Dr. David Harrington (Providence, Rhode Island): I rise to talk about the beta blockade in burns because this has been an ongoing interest of Dr. Herndon and the Galveston group.
Because of his persistent interest in this and because of the data he has now, through a DoD grant, are looking at this for adult patients and burn patients.
What's interesting is that the implications are that we, he felt that the beta blockade in burns does reduce hypermetabolism and improved outcome.
Your work and work from the shop in Loyola suggests that maybe what is going on is if we can just support blood cell production and reduce blood cell transfusion and reduce immunosuppression that this might be an additional mechanism of its benefit. I would love to see your group look at and sponsor a multiinstitutional trial for beta blockade in trauma patients and whether, what is the current use of beta blockade in adult burn, adult patients in trauma centers.
Thank you. Dr. Ines G. Alamo (Gainesville, Florida): Thank you Dr. Arbabi for your comments and questions. For your first question, as you mentioned, we previously have demonstrated and published that beta adrenergic receptors, specifically Beta 2 and Beta 3, play a key role in progenitor cell mobilization and erythroid colony growth.
However, we have also recently published that both erythroid cell growth and mobilization improve with the use of clonidine, a central sympatholytic that specifically inhibits the release of norepinephrine. Based on this, we believe this is more likely a reduction of the effects of norepinephrine than a specific receptor.
We have yet to directly link any adrenergic receptors to Hepcidin and the iron transport system. At this time it is likely that norepinephrine regulates the iron transport system via its direct impact on IL-6, transferrin, and its receptor.
In reference to your second question, yes we do believe this is mediated by IL-6, which is directly impacted by norepinephrine.
In our clinically relevant rodent model of severe trauma and chronic stress, we have measured liver IL-6 expression on Days 1 and 7 via end-point PCR. The addition of chronic stress to severe trauma, as illustrated by LCHS/CS, increased liver IL-6 expression on Day 1 and continued to remain persistent up to Day 7, compared to LCHS alone. Now with daily propranolol treatment we did suppress liver IL-6 expression but it was not significant. However, we also measured one specific acute phase protein produced by IL-6: CRP. CRP remains significantly elevated up to Day 7 in LCHS/ CS and was considerably reduced with daily propranolol treatment.
Regarding Dr. Harrington's question about how this works in adults, this translated to our human trauma study in which patients received daily propranolol treatment following severe injury. CRP and IL-6 levels of severely injured patients were significantly suppressed with daily propranolol.
In reference to your third question about EPO, we do believe the effects of beta-blocker therapy on plasma EPO levels are secondary to hemoglobin concentration. At this time we have not found a direct link between beta adrenergic receptors and EPO but in the future we are planning to pursue studies via knock-out mice and six-hydroxydopamine treatment.
Thank you.
